Program
cenvacibart
Also written as “REGN7508”, “Cenvacibart” and “REGN7508 (IV)”.
Its studies are mostly in Venous Thromboembolism · Atrial Fibrillation · Venous Thrombosis · Stroke · Kidney Failure, Chronic, led by Regeneron Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 1511 open or running | phase 3since Jun 3, 2025 | Oct 27, 2022 | Feb 9, 2027phase 2 · NCT07175428 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 27, 2022First study: phase 1 study in Healthy VolunteerFirst studyNCT05603195 · 80 enrolled · United Kingdom
- Mar 1, 2024Phase 2 study in Venous ThromboembolismNCT06299111 · 195 enrolled · United States, Bulgaria, Canada and more
- May 30, 2024Phase 1 study in HemorrhageNCT06444178 · 224 enrolled · United Kingdom
- Jun 6, 2024Phase 2 study in Venous ThromboembolismNCT06454630 · 179 enrolled · Bulgaria, Hungary, Latvia and more
- Jun 3, 2025Phase 3 study in Venous ThromboembolismNCT07015905 · 2,000 planned · United States, Bulgaria, Hungary and more
- Sep 9, 2025Phase 2 study in Atrial FibrillationNCT07175428 · 1,200 planned · United States, Argentina, Brazil and more
- Oct 3, 2025Phase 3 study in Venous ThrombosisNCT07213778 · 2,000 planned · United States, Greece, Malaysia and more
- Feb 6, 20262 phase 3 studiesNCT07410117, NCT07430956
- Mar 5, 2026Phase 3 study in Venous ThromboembolismNCT07493304 · 1,600 planned · United States, Bulgaria, Japan and more
- May 29, 2026Phase 3 study in Atrial FibrillationNCT07626411 · 15,364 planned · United States, Canada, Japan
- Jul 6, 2026Phase 3 study in Venous ThromboembolismNCT07697599 · 1,908 planned · Georgia
- Aug 6, 2026Phase 1 study in Kidney Failure, ChronicNCT07759167 · 36 planned · Belgium
- Oct 9, 2026Phase 1 study in Healthy VolunteersNCT07876505 · 80 planned
- Oct 9, 2026Phase 3 study in StrokeNCT07876492 · 6,106 planned
Ahead
- Feb 9, 2027Primary completion: phase 2 study in Atrial FibrillationNCT07175428
- Feb 20, 2027Primary completion: phase 3 study in Venous ThromboembolismNCT07015905
- Mar 23, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07876505
- Apr 2, 2027Primary completion: phase 1 study in Kidney Failure, ChronicNCT07759167
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07876505Healthy Volunteers | 1 | Not yet recruiting | Mar 23, 2027 | 80 |
| NCT07876492Stroke | 3 | Not yet recruiting | Dec 15, 2029 | 6,106 |
| NCT07759167Kidney Failure, Chronic · Belgium | 1 | Recruiting | Apr 2, 2027 | 36 |
| NCT07697599Venous Thromboembolism · Georgia | 3 | Recruiting | Jun 25, 2029 | 1,908 |
| NCT07626411Atrial Fibrillation · United States, Canada, Japan | 3 | Recruiting | Sep 11, 2029 | 15,364 |
| NCT07493304Venous Thromboembolism · United States, Bulgaria, Japan and more | 3 | Recruiting | Jul 18, 2031 | 1,600 |
| NCT07430956Atrial Fibrillation · United States, Canada | 3 | Recruiting | Mar 28, 2029 | 2,628 |
| NCT07410117Venous Thromboembolism · United States, Georgia, Japan | 3 | Recruiting | Jan 23, 2030 | 1,120 |
| NCT07213778Venous Thrombosis · United States, Greece, Malaysia and more | 3 | Recruiting | May 17, 2027 | 2,000 |
| NCT07175428Atrial Fibrillation · United States, Argentina, Brazil and more | 2 | Recruiting | Feb 9, 2027 | 1,200 |
| NCT07015905Venous Thromboembolism · United States, Bulgaria, Hungary and more | 3 | Recruiting | Feb 20, 2027 | 2,000 |
| NCT06454630Venous Thromboembolism · Bulgaria, Hungary, Latvia and more | 2 | Completed | Nov 19, 2024 | 179 |
| NCT06444178Hemorrhage · United Kingdom | 1 | Completed | Apr 7, 2025 | 224 |
| NCT06299111Venous Thromboembolism · United States, Bulgaria, Canada and more | 2 | Completed | Mar 27, 2026 | 195 |
| NCT05603195Healthy Volunteer · United Kingdom | 1 | Completed | Sep 17, 2024 | 80 |
How it is read
Names in the registry
- “REGN7508”, 12 entries
- “Cenvacibart”, 2 entries
- “REGN7508 (IV)”, 1 entry
- “REGN7508 (SC)”, 1 entry
Conditions, from the studies’ own filings
- Venous Thromboembolism, 6 studies
- Atrial Fibrillation, 3 studies
- Venous Thrombosis, 1 study
- Stroke, 1 study
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.